Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
71 participants
OBSERVATIONAL
2019-06-20
2022-06-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Surgical and Oncological Outcomes in Patients With Ulcerative Colitis-associated Rectal Cancer
NCT04659148
Treatment Outcomes of Advanced Neoplasia in IBD
NCT05674773
Bowel Function/QoL After Elective Sigmoidectomy vs. Conservative Management for Recurrent Uncomplicated Diverticulitis
NCT03994978
PReventive cOlostomy vs Ileostomy in Low anTErior reCTal Resection
NCT04357171
Comparison of Early Operative Treatment and 48 h Conservative Treatment in Small Bowel Obstruction
NCT03139149
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In the Russian clinical guidelines for the treatment of ulcerative colitis, the extremely severe ulcerative colitis is added to the classification of the severity.
The extremely severe ulcerative colitis is a severe, according to the criteria of Truelove, Witts and the endoscopic picture of deep, extensive ulcerative defects of the mucosa, up to the muscular layer with the formation of mucosal islets including albumin reduction.
Conservative treatment of patients with extremely severe ulcerative colitis worsens treatment outcomes only. The authors of the study want to prove that patients with a extremely severe ulcerative colitis need a colectomy in a short time.
Is there a need for long-term follow-up, conservative treatment of high-risk patients? Is it safe to perform early surgical treatment without long-term conservative treatment? This study will allow to answer these questions and help doctors in the treatment of such patients anywhere in Russia and not only.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
General group
Patient with extremely severe ulcerative colitis
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Extremely severe activity according endoscopic picture of deep, extensive ulcerative defects of the mucosa, up to the muscular layer with the formation of mucosal islets including albumin reduction (lower 31 g/l).
Exclusion Criteria
* Infectious, ischemic colitis;
* Transformation of diagnosis into Crohn's disease;
* Medical treatment failure before the admission.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
State Scientific Centre of Coloproctology, Russian Federation
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Achkasov Sergey
Achkasov Sergey, Professor of State Scientific Centre of Coloproctology, Head of sugery and oncology of colon department, Moscow
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ayrat Mingazov
Role: STUDY_CHAIR
Sub-investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
State Scientific Centre of Coloproctology, Russian Federation
Moscow, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
127
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.